← Leaderboards
Kenneth G Linden
University Of California, San Diego
$47,405
Attributed
$47,405
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $32.3K · FY2008–10$50K$37.5K$25K$12.5K$0
'08
'09
'10
Funding mix
By agency
NIH$47,405 · 3
By mechanism
M01$47,405 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Michael Karin$60,628,305
- J. Silvio Gutkind$14,229,551
- Scott T Weiss$73,772,324
- Michael Bouvet$7,522,814
- Murray B. Stein$36,454,107
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthResearch InfrastructureResearch PersonnelResourcesSourceChemopreventionClinical TrialsComputer Retrieval Of Information On Scientific Projects DatabaseDouble-Blind MethodDysplastic NevusFundingFutureGrantInstitutionLovastatinMelanomaMolecularPlacebo ControlPremalignantPrimary PreventionRandomizedResearch DesignBiomarkerBiological Markers
Grant awards (3)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II CLINICAL TRIAL OF LOVAST$4,142
M01 · FY2010 · RR · contact PI
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II CLLINICAL TRIAL OF LOVAST$32,272
M01 · FY2009 · RR · contact PI
RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED PHASE II CLINICAL TRIAL OF LOVASTATI$10,991
M01 · FY2008 · RR · contact PI